Irreversible vs Reversible Binding
Compare how reversible and irreversible drug-target interactions differ in duration and clinical impact.
## Introduction
The nature of drug-target binding—reversible or irreversible—fundamentally determines duration of action, dosing strategy, and safety profile. Most drugs bind reversibly, but a growing number of rationally designed covalent (irreversible) inhibitors have proven highly effective, particularly in oncology.
## Reversible Binding
Reversible drugs interact with targets through non-covalent forces: hydrogen bonds, van der Waals interactions, electrostatic attraction, and hydrophobic contacts. The drug continuously associates and dissociates, establishing a dynamic equilibrium described by the dissociation constant Kd = koff/kon.
Duration of action depends on the drug's residence time (1/koff) at the target rather than just its affinity. A slow off-rate means prolonged target occupancy even as plasma concentrations fall—explaining why some reversible drugs have effects outlasting their plasma half-life. Tiotropium, for example, has a residence time of ~35 hours at M3 muscarinic receptors despite modest affinity.
Reversible binding is generally considered safer because effects wane predictably as the drug is eliminated from the body.
## Irreversible Binding
Irreversible inhibitors form covalent bonds with the target, typically reacting with a nucleophilic amino acid residue (cysteine, serine, threonine, or lysine). The target is permanently inactivated; functional recovery requires de novo synthesis of new protein, which can take hours to days depending on turnover rate.
Many modern irreversible inhibitors use a two-step mechanism: initial reversible binding (recognition) followed by covalent bond formation (inactivation). The kinact/KI ratio quantifies covalent inhibitor potency—kinact is the maximum inactivation rate and KI is the concentration achieving half-maximal rate.
## Clinical Implications
Irreversible inhibitors can achieve sustained efficacy at lower plasma concentrations because target recovery depends on protein turnover, not drug exposure. However, off-target covalent modification raises toxicity concerns (e.g., hepatotoxicity), and adverse effects cannot be reversed by simply stopping the drug.
## Examples Across Drug Classes
- **Aspirin**: Irreversibly acetylates COX-1 Ser530; antiplatelet effect lasts 7–10 days
- **Omeprazole**: Covalently binds H+/K+-ATPase cysteine residues; requires new pump synthesis
- **Osimertinib**: Covalent EGFR inhibitor targeting Cys797 in T790M-mutant NSCLC
- **Metoprolol**: Reversible beta-1 antagonist; effect directly tracks plasma levels
## Key Takeaways
- Reversible drugs use non-covalent forces and establish dynamic binding equilibrium
- Irreversible drugs form covalent bonds, permanently inactivating the target
- Recovery from irreversible inhibition requires de novo protein synthesis
- Drug residence time (1/koff) can matter more than binding affinity for clinical duration